SER
Serina Therapeutics, Inc. AMEX Listed Jan 21, 2000$2.80
-1.75%
vs $2.85
Mkt Cap $42.0M
52w Low $1.22
23.6% of range
52w High $7.92
50d MA $2.09
200d MA $2.41
P/E (TTM)
—
EV/EBITDA
—
P/B
—
Debt/Equity
-5.3x
ROE
51843.2%
P/FCF
-1.6x
RSI (14)
85.00
ATR (14)
$0.16
Beta
0.10
50d MA
$2.09
200d MA
$2.41
Avg Volume
48.6K
Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson's disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson's disease; and SER 228 for the treatment of epilepsy. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc. was founded in 2006 and is based in Huntsville, Alabama.
601 Genome Way · Huntsville, AL 35806 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 25, 2026 | AMC | -0.50 | -0.31 | +38.0% | 3.03 | -8.9% | -13.9% | -13.0% | -20.7% | +7.8% | +9.3% | — |
| Nov 13, 2025 | AMC | -0.47 | -0.45 | +4.3% | 3.92 | +0.5% | +4.3% | -6.6% | -1.6% | +2.7% | -2.6% | — |
| Aug 11, 2025 | AMC | -0.36 | -0.66 | -83.3% | 5.10 | +0.0% | +7.1% | -1.6% | +2.4% | -1.8% | -3.1% | — |
| May 8, 2025 | AMC | -0.62 | -0.49 | +21.0% | 5.75 | +0.9% | -2.1% | +0.2% | +3.5% | -3.9% | +0.5% | — |
| Mar 24, 2025 | AMC | 0.42 | -0.27 | -164.3% | 4.84 | -0.8% | -4.5% | +5.0% | -2.1% | +11.4% | +7.2% | — |
| Nov 12, 2024 | AMC | — | 0.13 | — | 5.19 | -3.7% | -3.7% | +0.0% | -3.4% | +3.5% | +0.0% | — |
| Aug 9, 2024 | AMC | — | 0.51 | — | 7.14 | -4.6% | -10.1% | +8.3% | -1.6% | -2.6% | +7.2% | — |
| May 14, 2024 | AMC | — | -3.38 | — | 9.24 | -6.3% | -4.4% | -9.1% | +5.9% | +17.6% | -1.2% | — |
| Mar 22, 2024 | AMC | — | -3.20 | — | 13.03 | -3.8% | -3.3% | -11.9% | +34.0% | -9.5% | -12.1% | — |
| Nov 14, 2023 | AMC | — | -0.14 | — | 21.43 | +0.0% | -5.7% | +3.7% | -26.7% | -15.1% | +12.3% | — |
| Sep 29, 2023 | AMC | — | -5.01 | — | 24.29 | +0.0% | +2.3% | +6.3% | -5.4% | +2.8% | +2.1% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jul 1 | BTIG Research | Initiates | Buy | $8 | $1.94 | $2.00 | +3.1% | -1.0% | -1.0% | +2.6% | +11.3% | -7.8% |
| Aug 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.99 | $4.97 | -0.4% | +2.8% | +3.7% | -0.2% | -0.4% | -0.2% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jul 7, 2026 | Brannan Stephen K.Dir | — | Buy | 1,000 | $2.03 | $2K | 1,000 | -2.73% | +3.59% |
| Jun 12, 2026 | WILSON KAREN JDir | — | Buy | 5,000 | $1.77 | $9K | 10,100 | +6.81% | +3.17% |
| Jun 11, 2026 | WILSON KAREN JDir | — | Buy | 5,100 | $1.75 | $9K | 5,100 | +6.81% | +3.17% |
| May 22, 2026 | Venkatesan JayDir | — | Buy | 589 | $1.78 | $1K | 589 | +1.59% | +8.84% |
| May 22, 2026 | WILSON KAREN JDir | — | Buy | 10,000 | $1.93 | $19K | 20,000 | -6.25% | -2.76% |
| May 21, 2026 | WILSON KAREN JDir | — | Buy | 10,000 | $1.77 | $18K | 10,000 | -6.25% | -2.76% |
8-K · 2.02
!! High
Serina Therapeutics, Inc. -- 8-K 2.02: Earnings Results
Aug 13
8-K · 5.02
!!! Very High
Serina Therapeutics, Inc. -- 8-K 5.02: Executive Change
Steve Ledger's resignation as director of Serina Therapeutics (SER) reduces board oversight capacity, potentially signaling internal challenges or strategic shifts that investors should monitor closely.
Jul 23
8-K · 5.02
!!! Very High
Serina Therapeutics, Inc. -- 8-K 5.02: Executive Change
Serina Therapeutics appointed Farrell Simon as Chief Commercial Officer effective July 22, 2026, strengthening its commercial leadership ahead of potential product launches.
Jul 22
8-K · 5.03
! Medium
Serina Therapeutics, Inc. -- 8-K 5.03: Amendment to Articles / Bylaws
Serina Therapeutics changed its fiscal year-end, which may affect reporting timelines and investor expectations around earnings announcements and financial disclosures.
Jun 24
8-K · 2.02
!! High
Serina Therapeutics, Inc. -- 8-K 2.02: Earnings Results
May 14
8-K · 5.02
!!! Very High
Serina Therapeutics, Inc. -- 8-K 5.02: Executive Change
Serina Therapeutics appointed Srini Tenjarla as Senior Vice President, indicating organizational restructuring that could signal strategic shifts in operations or leadership priorities for the biotech company.
Apr 21
8-K
Unknown — 8-K Filing
Serina secured FDA clearance for SER-252's Phase 1b trial and raised $30 million in financing, demonstrating pipeline progress and extended runway that should reduce near-term dilution risks and support clinical development.
Mar 25
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
The departure of key officers at Sermonix suggests internal management instability following an acquisition, which could disrupt operations and negatively pressure SER's stock performance.
Mar 23
Institutional (13F) — Top 8
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Waverly Advisors, Llc | 67,492 | $131K | — | Mar 2026 |
| 2 | Linscomb Wealth, Inc. | 18,800 | $36K | — | Dec 2025 |
| 3 | Hightower Advisors, Llc | 11,980 | $23K | Reduced | Dec 2025 |
| 4 | Wells Fargo & Company/mn | 3,606 | $7K | New | Mar 2026 |
| 5 | Morgan Stanley | 16 | $30 | — | Dec 2025 |
| 6 | Ubs Group Ag | 5 | $10 | Reduced | Mar 2026 |
| 7 | Bnp Paribas Financial Markets | 2 | $4 | — | Mar 2026 |
| 8 | Rockefeller Capital Management L.p. | 2 | $4 | — | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 5
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Fidelity Extended Market Index Fund | 28,925 | $52K | Feb 2026 |
| 2 | iShares Micro-Cap ETF | 14,896 | $29K | Mar 2026 |
| 3 | Fidelity Series Total Market Index Fund | 4,739 | $9K | May 2026 |
| 4 | Ultra-Small Company Market Fund | 2,495 | $5K | Mar 2026 |
| 5 | Fidelity Total Market Index Fund | 2,592 | $5K | May 2026 |
Valuation
Market Cap
$42.0M
Enterprise Value
$25.7M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
-0.04x
P/B
—
P/S
323.02x
P/FCF
-1.59x
EV/EBITDA
—
Shares Out
10.2M
Financials (TTM)
Revenue
$130K
Net Income
-$21.3M
EBITDA
-$21.2M
Free Cash Flow
-$18.0M
Op Cash Flow
-$18.0M
EPS Basic
$-1.91
EPS Diluted
$-1.97
EPS Forward
$-1.41
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$7.0M
Total Liab.
$7.0M
Total Equity
-$37K
Cash
$3.1M
LT Debt
$196K
Book Value/Sh
$-0.00
Debt/Equity
-5.30x
Current Ratio
1.71
Quick Ratio
1.71
Returns & Growth
ROE
51843.2%
ROA
-276.0%
ROIC
-709.0%
Rev Growth YoY
+132.1%
EPS Growth YoY
-26.5%
Price Returns
2W
+40.0%
1M
+43.6%
3M
+70.7%
6M
+53.0%
12M
-48.1%
Technicals
52W High
$7.92
52W Low
$1.22
50d MA
$2.09
200d MA
$2.41
RSI (14)
85.00
ATR (14)
$0.16
Beta
0.10
Avg Volume
49K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
—
High
—
Low
—
Median
—
Data updated apr 27, 2026 12:46am
· Source: financialmodelingprep.com